Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 5,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $37.59, for a total transaction of $187,950.00. Following the transaction, the director now owns 14,830 shares of the company’s stock, valued at $557,459.70. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Avidity Biosciences Stock Performance
RNA opened at $39.91 on Thursday. Avidity Biosciences, Inc. has a 12 month low of $4.82 and a 12 month high of $42.00. The business has a 50-day moving average of $29.33 and a two-hundred day moving average of $20.54.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last released its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.02. The firm had revenue of $3.54 million during the quarter, compared to the consensus estimate of $7.09 million. Avidity Biosciences had a negative net margin of 2,103.78% and a negative return on equity of 37.98%. Research analysts predict that Avidity Biosciences, Inc. will post -3.15 EPS for the current fiscal year.
Institutional Trading of Avidity Biosciences
Wall Street Analyst Weigh In
Several research analysts recently issued reports on RNA shares. Chardan Capital lifted their price objective on Avidity Biosciences from $33.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, June 12th. Evercore ISI boosted their price target on Avidity Biosciences from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, June 12th. Bank of America increased their price objective on Avidity Biosciences from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Needham & Company LLC reissued a “buy” rating and issued a $35.00 target price on shares of Avidity Biosciences in a research note on Monday, June 10th. Finally, Cantor Fitzgerald began coverage on shares of Avidity Biosciences in a research note on Thursday, March 14th. They set an “overweight” rating and a $60.00 price target on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Avidity Biosciences presently has a consensus rating of “Buy” and a consensus target price of $44.29.
Read Our Latest Research Report on Avidity Biosciences
About Avidity Biosciences
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Further Reading
- Five stocks we like better than Avidity Biosciences
- ESG Stocks, What Investors Should Know
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.